Yahoo Web Search

Search results

1. www.linkedin.com › in › bohuang1980Bo Huang, PhD, FASA - Pfizer | LinkedIn

   www.linkedin.com › in › bohuang1980

   Bo Huang, PhD, FASA - Pfizer | LinkedIn. New York, New York, United States. 3K followers 500+ connections. View mutual connections with Bo. Welcome back. Pfizer. University of...

   • Connections: 500+
   • Followers: 2.7K

   • Works For: Pfizer
   • Occupation: Executive Director, Biostatistics, Pfizer

2. scholar.google.com › citations‪Bo Huang‬ - ‪Google Scholar‬

   scholar.google.com › citations

   • Cached

   ‪Executive Director, Head of Non-Malignant Hematology Statistics, Pfizer‬ - ‪‪Cited by 8,019‬‬ - ‪Biostatistics‬ - ‪clinical trials‬ - ‪adaptive designs‬

3. www.researchgate.net › profile › Bo-Huang-11Bo HUANG | Executive Director | PhD | Pfizer, New York City ...

   www.researchgate.net › profile › Bo-Huang-11

   Bo HUANG, Executive Director | Cited by 6,699 | of Pfizer, New York City | Read 121 publications | Contact Bo HUANG

4. www.linkedin.com › posts › bohuang1980_im-happy-toBo Huang, PhD, ASA Fellow’s Post - LinkedIn

   www.linkedin.com › posts › bohuang1980_im-happy-to

   Bo Huang, PhD, ASA Fellow. Executive Director, Biostatistics, Pfizer. 4mo. Avelumab is the SOC for first-line maintenance treatment of adults with urothelial carcinoma whose cancer has...

5. www.linkedin.com › posts › bohuang1980_in-thisBo Huang, PhD, FASA’s Post - LinkedIn

   www.linkedin.com › posts › bohuang1980_in-this

   Bo Huang, PhD, FASA. Executive Director, Biostatistics, Pfizer. 2mo. #Sickle_Cell_Disease (SCD) is caused by a mutation in the genes responsible for producing hemoglobin beta, an essential...

6. onlinelibrary.wiley.com › doi › 10Comparison of the restricted mean survival time with the ...

   onlinelibrary.wiley.com › doi › 10

   Pharmaceutical Statistics. Volume 17, Issue 3 p. 202-213. MAIN PAPER. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point. Bo Huang,Pei-Fen Kuan, First published: 28 December 2017. https://doi.org/10.1002/pst.1846. Citations: 41. Read the full text. PDF. Tools. Share. Abstract.

7. www.tandfonline.com › doi › fullNovel dose-finding designs and considerations on practical ...

   www.tandfonline.com › doi › full

   Jun 3, 2016 · Novel dose-finding designs and considerations on practical implementations in oncology clinical trials Bo Huang Pfizer Oncology, Pfizer Inc., Groton, Connecticut, USA Correspondence bo.huang@pfizer.com